Comparison

(Rac)-IBT6A European Partner

Item no. HY-13036-25mg
Manufacturer MedChem Express
CASRN 1412418-47-3
Amount 25 mg
Specific against other
Purity 98.18
Citations [1]Honigberg LA, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80.<br>[2]Liu N, et al. Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: a comparative study. Org Biomol Chem. 2015 May 14;13(18):5147-57.<br>[3]Somana Siva Prasad, et al. A QUALITY BY DESIGN APPROACH FOR DEVELOPMENT OF SIMPLE AND ROBUST REVERSED PHASE STABILITY INDICATING HPLC METHOD FOR ESTIMATION OF IBRUTINIB AND ITS IMPURITIES.
Available
Product Description
(Rac)-IBT6A is a racemate of IBT6A. IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct[1]. Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM[2].
StorageTemperature
-20°C, 3 years; 4°C, 2 years (Powder)
Shipping
Room Temperature
Manufacturers Applications
Neuroscience-Neuromodulation
MolecularWeight
386.45
Clinical_Information
No Development Reported
Manufacturers Research_Area
Cancer
Solubility
DMSO : 50 mg/mL (ultrasonic)
Pathway
Protein Tyrosine Kinase/RTK
Manufacturers Product type
Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 25 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close